Patents by Inventor Jaime E. Villegas
Jaime E. Villegas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230040280Abstract: The invention provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating and preventing metastasis or relapse of a cancer in an individual previously treated for cancer with a therapy. The invention also provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating a refractory cancer (e.g., a refractory HPV-associated cancer).Type: ApplicationFiled: March 25, 2022Publication date: February 9, 2023Inventors: Luis O. Burzio Eriz, Veronica A. Burzio Menendez, Jaime E. Villegas Olavarria
-
Patent number: 11319535Abstract: The invention provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating and preventing metastasis or relapse of a cancer in an individual previously treated for cancer with a therapy. The invention also provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating a refractory cancer (e.g., a refractory HPV-associated cancer).Type: GrantFiled: September 17, 2019Date of Patent: May 3, 2022Assignee: ANDES BIOTECHNOLOGIES GLOBAL, INC.Inventors: Luis O. Burzio Eriz, Veronica A. Burzio Menendez, Jaime E. Villegas Olavarria
-
Publication number: 20210348236Abstract: A novel family of human mitochondrial RNAs, referred to as chimeric RNAs, which are differentially expressed in normal, pre-cancer and cancer cells, are described. Oligonucleotides targeted to the chimeric RNAs are provided. The described oligonucleotides or their analogs can be used for cancer diagnostics and cancer therapy as well as for research. In one embodiment of this invention, these oligonucleotides hybridize with the sense or with the antisense mitochondrial chimeric RNAs, and the result of the hybridization is useful to differentiate between normal proliferating cells, pre-cancer cells and cancer cells. In another embodiment of the invention, the compositions comprise oligonucleotides that hybridize with the human chimeric RNAs resulting in cancer cell and pre-cancer cell death, while there is no effect in normal cells, constituting therefore, a novel approach for cancer therapy.Type: ApplicationFiled: November 24, 2020Publication date: November 11, 2021Inventors: Luis O. BURZIO, Jaime E. VILLEGAS, Veronica A. BURZIO
-
Patent number: 10876166Abstract: A novel family of human mitochondrial RNAs, referred to as chimeric RNAs, which are differentially expressed in normal, pre-cancer and cancer cells, are described. Oligonucleotides targeted to the chimeric RNAs are provided. The described oligonucleotides or their analogs can be used for cancer diagnostics and cancer therapy as well as for research. In one embodiment of this invention, these oligonucleotides hybridize with the sense or with the antisense mitochondrial chimeric RNAs, and the result of the hybridization is useful to differentiate between normal proliferating cells, pre-cancer cells and cancer cells. In another embodiment of the invention, the compositions comprise oligonucleotides that hybridize with the human chimeric RNAs resulting in cancer cell and pre-cancer cell death, while there is no effect in normal cells, constituting therefore, a novel approach for cancer therapy.Type: GrantFiled: January 10, 2018Date of Patent: December 29, 2020Assignee: Andes Biotechnologies Global, Inc.Inventors: Luis O. Burzio, Jaime E. Villegas, Veronica A. Burzio
-
Publication number: 20200239885Abstract: The invention provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating and preventing metastasis or relapse of a cancer in an individual previously treated for cancer with a therapy. The invention also provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating a refractory cancer (e.g., a refractory HPV-associated cancer).Type: ApplicationFiled: September 17, 2019Publication date: July 30, 2020Inventors: LUIS O. BURZIO ERIZ, VERONICA A. BURZIO MENENDEZ, JAIME E. VILLEGAS OLAVARRIA
-
Patent number: 10457943Abstract: The invention provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating and preventing metastasis or relapse of a cancer in an individual previously treated for cancer with a therapy. The invention also provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating a refractory cancer (e.g., a refractory HPV-associated cancer).Type: GrantFiled: November 29, 2017Date of Patent: October 29, 2019Assignee: Andes Biotechnologies Global Inc.Inventors: Luis O. Burzio Eriz, Veronica A. Burzio Menendez, Jaime E. Villegas Olavarria
-
Publication number: 20180340232Abstract: A novel family of human mitochondrial RNAs, referred to as chimeric RNAs, which are differentially expressed in normal, pre-cancer and cancer cells, are described. Oligonucleotides targeted to the chimeric RNAs are provided. The described oligonucleotides or their analogs can be used for cancer diagnostics and cancer therapy as well as for research. In one embodiment of this invention, these oligonucleotides hybridize with the sense or with the antisense mitochondrial chimeric RNAs, and the result of the hybridization is useful to differentiate between normal proliferating cells, pre-cancer cells and cancer cells. In another embodiment of the invention, the compositions comprise oligonucleotides that hybridize with the human chimeric RNAs resulting in cancer cell and pre-cancer cell death, while there is no effect in normal cells, constituting therefore, a novel approach for cancer therapy.Type: ApplicationFiled: January 10, 2018Publication date: November 29, 2018Inventors: Luis O. BURZIO, Jaime E. VILLEGAS, Veronica A. BURZIO
-
Patent number: 10066269Abstract: The invention provides methods for using the expression levels and subcellular localization of non-coding mitochondrial RNAs to select individuals or subpopulation of individuals for treatment with an anticancer therapy for multiple myeloma. Additional methods provided herein are useful for determining whether an individual in remission for multiple myeloma following successful treatment will be likely to suffer a relapse as well as to identify individuals who have suffered a relapse of multiple myeloma.Type: GrantFiled: March 14, 2014Date of Patent: September 4, 2018Assignee: ANDES BIOTECHNOLOGIES GLOBAL, INC.Inventors: Claudio E. Villota Arcos, Jaime E. Villegas Olavarria, Veronica A. Burzio Menendez, Luis O. Burzio Eriz
-
Publication number: 20180171335Abstract: The invention provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating and preventing metastasis or relapse of a cancer in an individual previously treated for cancer with a therapy. The invention also provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating a refractory cancer (e.g., a refractory HPV-associated cancer).Type: ApplicationFiled: November 29, 2017Publication date: June 21, 2018Inventors: Luis O. Burzio Eriz, Veronica A. Burzio Menendez, Jaime E. Villegas Olavarria
-
Patent number: 9903000Abstract: A novel family of human mitochondrial RNAs, referred to as chimeric RNAs, which are differentially expressed in normal, pre-cancer and cancer cells, are described. Oligonucleotides targeted to the chimeric RNAs are provided. The described oligonucleotides or their analogs can be used for cancer diagnostics and cancer therapy as well as for research. In one embodiment of this invention, these oligonucleotides hybridize with the sense or with the antisense mitochondrial chimeric RNAs, and the result of the hybridization is useful to differentiate between normal proliferating cells, pre-cancer cells and cancer cells. In another embodiment of the invention, the compositions comprise oligonucleotides that hybridize with the human chimeric RNAs resulting in cancer cell and pre-cancer cell death, while there is no effect in normal cells, constituting therefore, a novel approach for cancer therapy.Type: GrantFiled: April 26, 2016Date of Patent: February 27, 2018Assignee: Andes Biotechnologies Global, Inc.Inventors: Luis O. Burzio, Jaime E. Villegas, Veronica A. Burzio
-
Patent number: 9862944Abstract: The invention provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating and preventing metastasis or relapse of a cancer in an individual previously treated for cancer with a therapy. The invention also provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating a refractory cancer (e.g., a refractory HPV-associated cancer).Type: GrantFiled: March 14, 2014Date of Patent: January 9, 2018Assignee: ANDES BIOTECHNOLOGIES S.A.Inventors: Luis O. Burzio Eriz, Veronica A. Burzio Menendez, Jaime E. Villegas Olavarria
-
Publication number: 20160304971Abstract: A novel family of human mitochondrial RNAs, referred to as chimeric RNAs, which are differentially expressed in normal, pre-cancer and cancer cells, are described. Oligonucleotides targeted to the chimeric RNAs are provided. The described oligonucleotides or their analogs can be used for cancer diagnostics and cancer therapy as well as for research. In one embodiment of this invention, these oligonucleotides hybridize with the sense or with the antisense mitochondrial chimeric RNAs, and the result of the hybridization is useful to differentiate between normal proliferating cells, pre-cancer cells and cancer cells. In another embodiment of the invention, the compositions comprise oligonucleotides that hybridize with the human chimeric RNAs resulting in cancer cell and pre-cancer cell death, while there is no effect in normal cells, constituting therefore, a novel approach for cancer therapy.Type: ApplicationFiled: April 26, 2016Publication date: October 20, 2016Inventors: Luis O. BURZIO, Jaime E. VILLEGAS, Veronica A. BURZIO
-
Patent number: 9359648Abstract: A novel family of human mitochondrial RNAs, referred to as chimeric RNAs, which are differentially expressed in normal, pre-cancer and cancer cells, are described. Oligonucleotides targeted to the chimeric RNAs are provided. The described oligonucleotides or their analogs can be used for cancer diagnostics and cancer therapy as well as for research. In one embodiment of this invention, these oligonucleotides hybridize with the sense or with the antisense mitochondrial chimeric RNAs, and the result of the hybridization is useful to differentiate between normal proliferating cells, pre-cancer cells and cancer cells. In another embodiment of the invention, the compositions comprise oligonucleotides that hybridize with the human chimeric RNAs resulting in cancer cell and pre-cancer cell death, while there is no effect in normal cells, constituting therefore, a novel approach for cancer therapy.Type: GrantFiled: September 5, 2014Date of Patent: June 7, 2016Assignee: Andes Biotechnoogies S.A.Inventors: Luis Burzio, Jaime E. Villegas, Veronica A. Burzio
-
Publication number: 20160138109Abstract: The invention provides methods for using the expression levels and subcellular localization of non-coding mitochondrial RNAs to select individuals or subpopulation of individuals for treatment with an anticancer therapy for multiple myeloma. Additional methods provided herein are useful for determining whether an individual in remission for multiple myeloma following successful treatment will be likely to suffer a relapse as well as to identify individuals who have suffered a relapse of multiple myeloma.Type: ApplicationFiled: March 14, 2014Publication date: May 19, 2016Inventors: Claudio E. VILLOTA ARCOS, Jaime E. VILLEGAS OLAVARRIA, Veronica A. BURZIO MENENDEZ, Luis O. BURZIO ERIZ
-
Publication number: 20160138015Abstract: The invention provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating and preventing metastasis or relapse of a cancer in an individual previously treated for cancer with a therapy. The invention also provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating a refractory cancer (e.g., a refractory HPV-associated cancer).Type: ApplicationFiled: March 14, 2014Publication date: May 19, 2016Applicant: Andes Biotechnologies S.A.Inventors: Luis O. BURZIO ERIZ, Veronica A. BURZIO MENENDEZ, Jaime E. VILLEGAS OLAVARRIA
-
Publication number: 20150064700Abstract: A novel family of human mitochondrial RNAs, referred to as chimeric RNAs, which are differentially expressed in normal, pre-cancer and cancer cells, are described. Oligonucleotides targeted to the chimeric RNAs are provided. The described oligonucleotides or their analogs can be used for cancer diagnostics and cancer therapy as well as for research. In one embodiment of this invention, these oligonucleotides hybridize with the sense or with the antisense mitochondrial chimeric RNAs, and the result of the hybridization is useful to differentiate between normal proliferating cells, pre-cancer cells and cancer cells. In another embodiment of the invention, the compositions comprise oligonucleotides that hybridize with the human chimeric RNAs resulting in cancer cell and pre-cancer cell death, while there is no effect in normal cells, constituting therefore, a novel approach for cancer therapy.Type: ApplicationFiled: September 5, 2014Publication date: March 5, 2015Inventors: Luis BURZIO, Jaime E. VILLEGAS, Veronica A. BURZIO
-
Patent number: 8895719Abstract: A novel family of human mitochondrial RNAs, referred to as chimeric RNAs, which are differentially expressed in normal, pre-cancer and cancer cells, are described. Oligonucleotides targeted to the chimeric RNAs are provided. The described oligonucleotides or their analogs can be used for cancer diagnostics and cancer therapy as well as for research. In one embodiment of this invention, these oligonucleotides hybridize with the sense or with the antisense mitochondrial chimeric RNAs, and the result of the hybridization is useful to differentiate between normal proliferating cells, pre-cancer cells and cancer cells. In another embodiment of the invention, the compositions comprise oligonucleotides that hybridize with the human chimeric RNAs resulting in cancer cell and pre-cancer cell death, while there is no effect in normal cells, constituting therefore, a novel approach for cancer therapy.Type: GrantFiled: September 26, 2012Date of Patent: November 25, 2014Assignee: Andes Biotechnologies S.A.Inventors: Luis Burzio, Jaime E. Villegas, Veronica A. Burzio
-
Patent number: 8318686Abstract: A novel family of human mitochondrial RNAs, referred to as chimeric RNAs, which are differentially expressed in normal, pre-cancer and cancer cells, are described. Oligonucleotides targeted to the chimeric RNAs are provided. The described oligonucleotides or their analogs can be used for cancer diagnostics and cancer therapy as well as for research. In one embodiment of this invention, these oligonucleotides hybridize with the sense or with the antisense mitochondrial chimeric RNAs, and the result of the hybridization is useful to differentiate between normal proliferating cells, pre-cancer cells and cancer cells. In another embodiment of the invention, the compositions comprise oligonucleotides that hybridize with the human chimeric RNAs resulting in cancer cell and pre-cancer cell death, while there is no effect in normal cells, constituting therefore, a novel approach for cancer therapy.Type: GrantFiled: May 21, 2004Date of Patent: November 27, 2012Assignee: Andes Biotechnologies S.A.Inventors: Luis O. Burzio, Jaime E. Villegas, Veronica A. Burzio